Drug Trial Radar · NCT06134271
Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
160
Planned (sponsor's estimate)
Start
Nov 15, 2023
Primary completion
Apr 30, 2025
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Jianbin BiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, prospective, cohort study enrolled patients with metastatic hormone-sensitive prostate cancer who had been treated with other novel endocrine or systemic regimens (excluding patients treated with pre-order chemotherapy alone or bicalutamide); To observe the efficacy and safety of rezvilutamide alone or in combination with abiraterone in hormone-sensitive prostate cancer patients with PSA progression following prior sequence therapy.
Conditions
- Metastatic Hormone-Sensitive Prostate Cancer
Interventions
RezvilutamideDrug
Rezvilutamide 240mg qd
Rezvilutamide plus abirateroneDrug
Rezvilutamide 240mg qd plus abiraterone 1000mg + prednisone 5 mg qd
Continue previous treatmentDrug
Continue using the previous treatment regimen for treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to castration-resistant prostate cancer (CRPC)Time frame: From the first day of patient enrollment until the time reach CRPC, the duration of the assessment should not exceed 24 months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.